Patient's surgical risk for potentially resectable advanced thoracic esophageal cancer is not negatively impacted by neoadjuvant chemotherapy, study finds.
Data presented at the 2021 ASCO Gastrointestinal Cancers Symposium found that health-related quality of life was steady and similar over the course of 18 weeks for patients receiving chemotherapy with or without pembrolizumab for esophageal cancer.
The approval was based on results from the phase 2 DESTINY-Gastric01 trial which evaluated patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least 2 prior regimens.
Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.
Similar results with nivolumab and a matched placebo are reported with preliminary health-related quality-of-life data from the CheckMate 577 trial.
Stage 4 gastrointestinal stromal tumors were analyzed through a database query, results of which were presented in a poster at a recent medical meeting.
Statistically significant improvements in median progression-free survival were observed in patients with HER2- amplified disease who were treated with pembrolizumab in combination with trastuzumab and cisplatin plus capecitabine compared with those without HER2-amplified disease.
The phase 1b/2 PLANET study demonstrated promising results for patients with these rare gastrointestinal cancers.
The phase 2 study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium reported a total of 2 responses at the interim analysis, meeting criteria to continue accrual.
The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.
Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.
Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.
Investigators whose work was published in JAMA Network Open found that patients with low mammographic breast density were at higher risk of developing severe lymphedema.
A recent study revealed that by using standardized uptake value thresholds as determined by 2-[18F]-FDG PET/CT, investigators were able to predict the occurrence of Richter syndrome in patients with CLL.
IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.
Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.
The addition of the monoclonal antibody blinatumomab to hyper-CVAD could represent a potential option for extending remission times in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.
A study found that patients without recurrence of their oropharyngeal cancer at 5 years who were treated with intensity-modulated radiation therapy and had less tobacco exposure experienced optimal survival, but still had poorer outcomes when compared with the general population.
The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.
The study assessed the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E–mutated metastatic CRC who had been previously treated with 1 or 2 regimens.
“Based on the results of the QUAZAR study, it is very exciting to think that, by taking a tablet that is relatively well tolerated, we can help reduce relapse risk and improve survival,” lead study author Andrew H. Wei, MB, BS, PhD, said in a press release.
An industry leader in psychosocial oncology detailed the importance of patient-reported outcomes to the field as a whole and emphasized a number of key details to remember when examining these end points.
Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.
A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.
Though the majority of immune-related adverse events (irAEs) can be managed with corticosteroids and other immunosuppressive treatments, life-threatening and sometimes fatal events have still been reported thus revealing a need to develop measures for effective management.
The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.
A group launched by the Global Health Research Unit of the National Institute for Health Research, which is currently seeking to determine the best surgical practices for cancer treatments, found that there is no additional risk of contracting COVID-19 for patients with cancer of the head and neck.
The clinical investigator and her colleagues sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
A study of simulated patients with primary epithelial ovarian cancer found that none of the maintenance therapy regimens evaluated were cost-effective when compared with observation following frontline response.
